FormWeb • asparaginase erwinia chrysanthemi

UNC Health

UNC Health Medication Formulary

Change Request Form Chemical/SDS Search UNC Health.org

Add Formweb to your mobile device

Android iOS

Click here to submit safety event reports via SAFE

UNC Health

UNC Health Medication Formulary

Change Request Form Chemical/SDS Search UNC Health.org

Search results for:

asparaginase erwinia chrysanthemi

asparaginase erwinia chrysanthemi

Drug Name	Form	Strength	ARHS	Blue Ridge	Caldwell	Chatham	Johnston	Lenoir	Medical Center	Nash	Pardee	Rex	Rockingham	Southeastern	Wayne	Youth Behavioral Health
Asparaginase Erwinia Chrysanthemi, Recombinant	POWDER FOR INJECTION, INJECTABLE	20 mg/mL (0.5 mL)

UNC Health

System Formulary Restriction:

Inpatient use of asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze) is restricted to patients who meet all of the following:

Patients ≥ 1 month of age with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL)
Documented hypersensitivity reactions to pegylated asparaginase products
Orders must be signed by a Hematology/Oncology Physician

Use for all other indications is restricted to outpatient encounters or clinic use only (ie, no inpatient use)

Last updated: Aug. 29, 2023

Black Box Warning: Note: Latest labeling (3/2007) does not include prior boxed warning.

This site is intended for the staff of UNC Health.
While others may view accessible pages, UNC Health makes no warranty, express or implied,
as to the use of this information outside of UNC Health.